| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,233 | 0,261 | 16:37 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.10. | Oncodesign Precision Medicine (OPM): OPM Announces Its 2026 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position | 561 | Business Wire | OPM-201: secured funding from the Michael J. Fox Foundation to support the development of the LARKIN program in Parkinson's disease OPM-101: continued preparation for the REVERT Phase 1b/2a... ► Artikel lesen | |
| 08.10. | Oncodesign Precision Medicine Advances OPM-201 Toward Phase 1b Parkinson's Disease Trial | 3 | pulse2.com | ||
| 07.10. | Oncodesign Precision Medicine: OPM Achieved Several Major Scientific and Regulatory Milestones as Part of the LARKIN Program, Supported With Funding By The Michael J. Fox Foundation for Parkinson's Research (MJFF) | 618 | Business Wire | MJFF confirms its support to the program with the payment of an additional funding tranche Successful micronization of the active pharmaceutical ingredient and manufacturing of the first... ► Artikel lesen | |
| 30.04. | Oncodesign Precision Medicine (OPM): OPM Announces Its 2025 Annual Results and Provides an Update on Its Clinical Developments | 800 | Business Wire | Continued development of OPM-101 with Phase 1 clinical validation and approval to initiate the REVERT study (Phase 1b/2a in oncology) Significant progress with OPM-201: independent validation... ► Artikel lesen | |
| 03.03. | Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson's Disease | 806 | Business Wire | The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson's disease and the execution of long-term toxicology study including... ► Artikel lesen | |
| ONCODESIGN PRECISION MEDICINE Aktie jetzt für 0€ handeln | |||||
| 08.01. | Oncodesign Precision Medicine and Ksilink Join Forces to Test the Nanocyclix Chemical Library in Cell Models Derived From Patients With Serious Central Nervous System Diseases | 538 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker symbol: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant... ► Artikel lesen | |
| 29.12.25 | Oncodesign Precision Medicine and Navigo Proteins Announce the End of Their Collaboration in the Development of Radiotheranostics | 495 | Business Wire | Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| CG ONCOLOGY | 83,37 | +4,21 % | Guggenheim raises CG Oncology stock price target on trial results | ||
| SUMMIT THERAPEUTICS | 10,680 | +1,71 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| PRAXIS PRECISION MEDICINES | 318,84 | +4,52 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| RECURSION PHARMACEUTICALS | 2,875 | +5,70 % | Recursion auf der Jefferies Global Healthcare Conference: KI-Pipeline gewinnt an klinischer Dynamik | ||
| KYMERA THERAPEUTICS | 120,30 | -1,00 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,850 | +4,00 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| BIONTECH | 75,35 | -1,63 % | BioNTech-Aktie: Totes Kapital? | Die Aktie von BioNTech bleibt trotz des rückläufigen Impfstoffgeschäfts ein spannender Titel am Aktienmarkt. Anleger richten ihren Blick zunehmend auf die milliardenschwere Forschungspipeline im Bereich... ► Artikel lesen | |
| EVOTEC | 2,728 | 0,00 % | Evotec-Aktie: Gewinn- und Umsatzrekord? | Die Aktie des Hamburger Wirkstoffforschers Evotec bleibt ein spannender, aber risikoreicher Titel am deutschen Aktienmarkt. Nach schwierigen Monaten sorgen erste operative Fortschritte, neue Partnerschaften... ► Artikel lesen | |
| ERASCA | 14,140 | +2,61 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| MODERNA | 176,48 | -1,56 % | Moderna, Bayer, Merck investieren Milliarden - doch bei Psychedelika fehlt ein entscheidendes Teil | ||
| DYNE THERAPEUTICS | 16,405 | +2,40 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| COGENT BIOSCIENCES | 28,390 | +1,94 % | Cogent Biosciences auf Jefferies-Konferenz: Markteinführungspläne hängen an Bezuclastinib | ||
| VOR BIOPHARMA | 18,150 | +1,79 % | Vor Biopharma auf der Jefferies Global Healthcare Conference: Finanzstarker Vorstoß bei Autoimmunerkrankungen | ||
| ABSCI | 8,360 | +2,14 % | Absci auf der Jefferies Global Healthcare Conference: Milliardenmarkt für neuartigen Haarausfall-Wirkstoff im Fokus |